Doxorubicin inhibits osteosarcoma progression by regulating circ_0000006/miR-646/ BDNF axis

J Orthop Surg Res. 2021 Oct 30;16(1):645. doi: 10.1186/s13018-021-02782-y.

Abstract

Background: Osteosarcoma (OS) is the most common aggressive bone tumor in children and teenagers. Doxorubicin (DOX) is a chemotherapeutic drug for OS. This study aims to reveal the effects and underneath mechanism of DOX treatment in OS progression.

Methods: The expression of circular_0000006 (circ_0000006), microRNA-646 (miR-646) and brain-derived neurotrophic factor (BDNF) was detected by quantitative real-time polymerase chain reaction (qRT-PCR). BDNF protein expression was determined by western blot. Cell proliferation was illustrated by cell counting kit-8 (CCK-8) and cell colony formation assays. Cell migration and invasion were revealed by transwell migration and wound-healing assays and transwell invasion assay, respectively. Cell apoptosis was demonstrated by flow cytometry analysis. The binding relationship of miR-646 and circ_0000006 or BDNF was predicted by circRNA interactome and targetscan online database, respectively, and verified by dual-luciferase reporter assay. The effects of circ_0000006 knockdown on tumor growth in vivo were manifested by in vivo tumor formation assay.

Results: Circ_0000006 expression and the mRNA and protein levels of BDNF were dramatically upregulated, and miR-646 expression was effectively downregulated in OS tissues or cells compared with control groups. Circ_0000006 expression and BDNF protein expression were lower, and miR-646 expression was higher in DOX treatment groups than in control groups in OS cells. Circ_0000006 knockdown repressed cell proliferation, migration and invasion, whereas promoted cell apoptosis under DOX treatment in OS cells; however, these effects were attenuated by miR-646 inhibitor. Additionally, circ_0000006 sponged miR-646 to bind to BDNF. Circ_0000006 silencing suppressed tumor growth in vivo.

Conclusion: Circ_0000006 knockdown promoted DOX-mediated effects on OS development by miR-646/BDNF pathway, which provided a theoretical basis in treating OS with DOX.

Keywords: BDNF; DOX; Osteosarcoma; circ_0000006; miR-646.

MeSH terms

  • Brain-Derived Neurotrophic Factor / genetics
  • Disease Progression
  • Doxorubicin / pharmacology
  • Gene Expression Regulation, Neoplastic
  • Humans
  • MicroRNAs / genetics
  • Osteosarcoma* / drug therapy
  • Osteosarcoma* / genetics
  • RNA, Circular

Substances

  • Brain-Derived Neurotrophic Factor
  • MIRN646 microRNA, human
  • MicroRNAs
  • RNA, Circular
  • BDNF protein, human
  • Doxorubicin